Synapse

← Meletios Α. Dimopoulos

Papers by Meletios Α. Dimopoulos

Page 10 · newest first

  1. Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasoneBlood Advances · 2019
  2. Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline TherapyHemaSphere · 2019
  3. Low Bone Mineral Density and High Bone Turnover in Patients With Non-Hodgkin's Lymphoma (NHL) Who Receive Frontline Therapy: Results of a Multicenter Prospective StudyHemaSphere · 2019
  4. P1573Chemotherapy-induced vasotoxicity in patients undergoing therapy for breast cancerEuropean Heart Journal · 2019
  5. Modelization of Blood-Borne Hypercoagulability in Myeloma: A Tissue-Factor-Bearing Microparticle-Driven ProcessTH Open · 2019
  6. Non‐lethal proteasome inhibition activates pro‐tumorigenic pathways in multiple myeloma cellsJournal of Cellular and Molecular Medicine · 2019
  7. Screening for Gaucher disease among patients with plasma cell dyscrasiasLeukemia & lymphoma/Leukemia and lymphoma · 2019
  8. How I treat Waldenström macroglobulinemiaBlood · 2019
  9. Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma NetworkHaematologica · 2019
  10. Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple MyelomaNew England Journal of Medicine · 2019
  11. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trialLeukemia · 2019
  12. Reactive Vasodilation Predicts Mortality in Primary Systemic Light-Chain AmyloidosisCirculation Research · 2019
  13. Evaluating ibrutinib in the treatment of symptomatic Waldenstrom’s macroglobulinemiaJournal of Blood Medicine · 2019
  14. A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcomeSHILAP Revista de lepidopterología · 2019
  15. Monoclonal antibodies against RANKL and sclerostin for myeloma-related bone disease: can they change the standard of care?Expert Review of Hematology · 2019
  16. Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myelomaAnnals of Hematology · 2019
  17. Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studiesHaematologica · 2019
  18. Updated risk stratification model for smoldering multiple myeloma (SMM) incorporating the revised IMWG diagnostic criteria.Journal of Clinical Oncology · 2019
  19. Bortezomib, lenalidomide, and dexamethasone (VRd) ± daratumumab (DARA) in patients (pts) with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): A multicenter, randomized, phase III study (PERSEUS).Journal of Clinical Oncology · 2019
  20. Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m2 vs. twice-weekly 27 mg/m2 carfilzomib (randomized A.R.R.O.W. study)Leukemia · 2019
  21. Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and SubgroupsClinical Lymphoma Myeloma & Leukemia · 2019
  22. Evaluation of MET T1010I and MET rs40239 single-nucleotide polymorphisms in triple-negative breast cancer: a case–control studyOncoTargets and Therapy · 2019
  23. Progression Risk Stratification of Asymptomatic Waldenström MacroglobulinemiaJournal of Clinical Oncology · 2019
  24. Updates on thrombotic events associated with multiple myelomaExpert Review of Hematology · 2019
  25. Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studiesEuropean Journal Of Haematology · 2019
  26. Meat, fish, dairy products and risk of hematological malignancies in adults – a systematic review and meta-analysis of prospective studiesLeukemia & lymphoma/Leukemia and lymphoma · 2019
  27. Toll-Like Receptor 4 Activation Promotes Multiple Myeloma Cell Growth and Survival Via Suppression of The Endoplasmic Reticulum Stress Factor ChopScientific Reports · 2019
  28. Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myelomaBlood · 2019
  29. Anti-BCMA antibodies in the future management of multiple myelomaExpert Review of Anticancer Therapy · 2019
  30. The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG)Blood Cancer Journal · 2019
  31. Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myelomaBlood Cancer Journal · 2019
  32. Bone marrow biopsy in low‐risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk groupAmerican Journal of Hematology · 2019
  33. Myeloma bone disease: from biology findings to treatment approachesBlood · 2019
  34. Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial HypertensionJournal of Internal Medicine · 2019
  35. High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myelomaBlood · 2019
  36. A new genetic variant of hereditary apolipoprotein A-I amyloidosis: a case-report followed by discussion of diagnostic challenges and therapeutic optionsBMC Medical Genetics · 2019
  37. Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myelomaInternational Journal of Cancer · 2019
  38. Vulnerability variables among octogenerian myeloma patients: a single-center analysis of 110 patientsLeukemia & lymphoma/Leukemia and lymphoma · 2019
  39. Anthropometric characteristics, physical activity and risk of hematological malignancies: A systematic review and meta‐analysis of cohort studiesInternational Journal of Cancer · 2019
  40. Hereditary systemic amyloidosis caused by K19T apolipoprotein C-II variantAmyloid · 2019
  41. Optimizing Immunomodulatory Drug With Proteasome Inhibitor Combinations in Newly Diagnosed Multiple MyelomaThe Cancer Journal · 2019
  42. Development of an Initial Conceptual Model of Multiple Myeloma to Support Clinical and Health Economics Decision MakingMDM Policy & Practice · 2019
  43. Insights on Multiple Myeloma Treatment StrategiesHemaSphere · 2018
  44. Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonatesAmerican Journal of Hematology · 2018
  45. How I treat elderly patients with plasma cell dyscrasiasAging · 2018
  46. Bortezomib retreatment for relapsed and refractory multiple myeloma in real‐world clinical practiceHealth Science Reports · 2018
  47. Management of uterine sarcomas and prognostic indicators: real world data from a single-institutionBMC Cancer · 2018
  48. Clinical and biological implications of Hippo pathway dysregulation in sarcomasForum of Clinical Oncology · 2018
  49. One-Year Update of a Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Patients (Pts) with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): AlcyoneBlood · 2018
  50. Three-Year Follow up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM)Blood · 2018